Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Boccia

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Blood|November 10, 2023
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, et al.
The Oncologist|February 26, 2016
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases OnlyJohanna C Bendell, Ahmed Zakari, James D Peyton, et al.
Journal of Hematology & Oncology|May 2, 2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Azra Raza, Naomi Galili, Deborah Mulford, et al.
Hematological Oncology|July 27, 2023
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 studyMehdi Hamadani, Morton Coleman, Ralph Boccia, et al.
British Journal of Haematology|December 9, 2022
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myelomaJames R Berenson, Daisy Martinez, Tahmineh Safaie, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
Targeted Oncology|April 20, 2024
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and MethylprednisoloneJames R Berenson, Andrea Limon, Stephanie Rice, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
British Journal of Haematology|October 3, 2006
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm studyJames R Berenson, Ralph Boccia, David Siegel, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Blood|November 10, 2023
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, et al.
The Oncologist|February 26, 2016
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases OnlyJohanna C Bendell, Ahmed Zakari, James D Peyton, et al.
Journal of Hematology & Oncology|May 2, 2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Azra Raza, Naomi Galili, Deborah Mulford, et al.
Hematological Oncology|July 27, 2023
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 studyMehdi Hamadani, Morton Coleman, Ralph Boccia, et al.
British Journal of Haematology|December 9, 2022
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myelomaJames R Berenson, Daisy Martinez, Tahmineh Safaie, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
Targeted Oncology|April 20, 2024
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and MethylprednisoloneJames R Berenson, Andrea Limon, Stephanie Rice, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
British Journal of Haematology|October 3, 2006
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm studyJames R Berenson, Ralph Boccia, David Siegel, et al.
Pageof 5